RxDoctor Payments Data

Philip Kasmarcik, NP

Family · Newark Valley, NYNPI 1982165593

Payments from drug & device makers

$1,063in general payments, 2019–2025

Across 45 payments — averaging $23.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$746
  • E.r. Squibb & Sons, L.L.C.$125
  • Novo Nordisk$107
  • Boehringer Ingelheim$34
  • Johnson & Johnson$21
  • Xeris Pharmaceuticals, Inc.$17
  • plus $13 from 1 others

What the payments were for

  • Food & beverage$1,063100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,063 in reported general payments places this provider in the 70th percentile of 8,883 family providers in New York.

See all family providers in New York

Medicare billing

Part B allowed, 2024
$13,207
Medicare patients
90
Services billed
183

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban39$50,583
TrulicityDulaglutide26$48,992
OzempicSemaglutide30$41,227
EntrestoSacubitril/Valsartan25$33,900
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$29,708
XareltoRivaroxaban17$27,680
FarxigaDapagliflozin Propanediol16$25,207
OxycontinOxycodone Hcl24$18,551
JanuviaSitagliptin Phosphate11$18,513
JardianceEmpagliflozin16$17,449
VraylarCariprazine Hcl12$15,977
Breo ElliptaFluticasone/Vilanterol27$15,517
Repatha SureclickEvolocumab12$8,365
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr18$8,193
Advair HfaFluticasone Propion/Salmeterol21$7,548

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$107$41,22730 claims
Johnson & JohnsonXarelto$21$27,68017 claims
Boehringer IngelheimJardiance$34$17,44916 claims
AbbVieVraylar$746$15,97712 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 8,883 family providers in New York.

Other family in Newark Valley

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →